Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients

C. Rossi, M. Zucchetti, C. Sessa, R. Urso, C. Mangioni, M. D'Incalci

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Plasma levels of VM26 were assayed by HPLC in six ovarian cancer patients with normal renal and liver function who received the drugs as an initial 1-h IV infusion of 80 mg/m2 followed by a 24-h IV infusion of 120 mg/m2. These doses and infusion rates were chosen on the basis of mean VM26 clearance values found in a previous study, with the aim of reaching plasma steady-state levels of approximately 6 μg/ml in a short time. Plasma steady-state levels of 4-10 μg/ml, close to those predicted theoretically, were in fact attained at 4-9 h during the second, slower infusion. Mean half-lives and clearance values were 8.6±1.1 h and 0.78±0.08 l/h/m2. Six percent of the VM26 dose was recovered as unchanged drug in the urines collected up to 24 h after the end of infusion. The glucuronide of VM26 aglycone (4′-demethylepipodophyllotoxin) was identified in the urine of all patients, in amounts corresponding to about 8% of the drug dose.

Original languageEnglish
Pages (from-to)211-214
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume13
Issue number3
DOIs
Publication statusPublished - Oct 1984

Fingerprint

Pharmacokinetics
Ovarian Neoplasms
Plasmas
Urine
Pharmaceutical Preparations
Glucuronides
Liver
High Pressure Liquid Chromatography
Kidney

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients. / Rossi, C.; Zucchetti, M.; Sessa, C.; Urso, R.; Mangioni, C.; D'Incalci, M.

In: Cancer Chemotherapy and Pharmacology, Vol. 13, No. 3, 10.1984, p. 211-214.

Research output: Contribution to journalArticle

@article{7f6655572c1c464ba7f95f5cc3d1fe66,
title = "Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients",
abstract = "Plasma levels of VM26 were assayed by HPLC in six ovarian cancer patients with normal renal and liver function who received the drugs as an initial 1-h IV infusion of 80 mg/m2 followed by a 24-h IV infusion of 120 mg/m2. These doses and infusion rates were chosen on the basis of mean VM26 clearance values found in a previous study, with the aim of reaching plasma steady-state levels of approximately 6 μg/ml in a short time. Plasma steady-state levels of 4-10 μg/ml, close to those predicted theoretically, were in fact attained at 4-9 h during the second, slower infusion. Mean half-lives and clearance values were 8.6±1.1 h and 0.78±0.08 l/h/m2. Six percent of the VM26 dose was recovered as unchanged drug in the urines collected up to 24 h after the end of infusion. The glucuronide of VM26 aglycone (4′-demethylepipodophyllotoxin) was identified in the urine of all patients, in amounts corresponding to about 8{\%} of the drug dose.",
author = "C. Rossi and M. Zucchetti and C. Sessa and R. Urso and C. Mangioni and M. D'Incalci",
year = "1984",
month = "10",
doi = "10.1007/BF00269031",
language = "English",
volume = "13",
pages = "211--214",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients

AU - Rossi, C.

AU - Zucchetti, M.

AU - Sessa, C.

AU - Urso, R.

AU - Mangioni, C.

AU - D'Incalci, M.

PY - 1984/10

Y1 - 1984/10

N2 - Plasma levels of VM26 were assayed by HPLC in six ovarian cancer patients with normal renal and liver function who received the drugs as an initial 1-h IV infusion of 80 mg/m2 followed by a 24-h IV infusion of 120 mg/m2. These doses and infusion rates were chosen on the basis of mean VM26 clearance values found in a previous study, with the aim of reaching plasma steady-state levels of approximately 6 μg/ml in a short time. Plasma steady-state levels of 4-10 μg/ml, close to those predicted theoretically, were in fact attained at 4-9 h during the second, slower infusion. Mean half-lives and clearance values were 8.6±1.1 h and 0.78±0.08 l/h/m2. Six percent of the VM26 dose was recovered as unchanged drug in the urines collected up to 24 h after the end of infusion. The glucuronide of VM26 aglycone (4′-demethylepipodophyllotoxin) was identified in the urine of all patients, in amounts corresponding to about 8% of the drug dose.

AB - Plasma levels of VM26 were assayed by HPLC in six ovarian cancer patients with normal renal and liver function who received the drugs as an initial 1-h IV infusion of 80 mg/m2 followed by a 24-h IV infusion of 120 mg/m2. These doses and infusion rates were chosen on the basis of mean VM26 clearance values found in a previous study, with the aim of reaching plasma steady-state levels of approximately 6 μg/ml in a short time. Plasma steady-state levels of 4-10 μg/ml, close to those predicted theoretically, were in fact attained at 4-9 h during the second, slower infusion. Mean half-lives and clearance values were 8.6±1.1 h and 0.78±0.08 l/h/m2. Six percent of the VM26 dose was recovered as unchanged drug in the urines collected up to 24 h after the end of infusion. The glucuronide of VM26 aglycone (4′-demethylepipodophyllotoxin) was identified in the urine of all patients, in amounts corresponding to about 8% of the drug dose.

UR - http://www.scopus.com/inward/record.url?scp=0021130598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021130598&partnerID=8YFLogxK

U2 - 10.1007/BF00269031

DO - 10.1007/BF00269031

M3 - Article

VL - 13

SP - 211

EP - 214

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -